Targeting the "undruggable": RNA-binding proteins in the spotlight in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Tumors resistant to conventional therapy often contain subpopulations with increased mutations or epigenetic changes.
• Aberrant expression of RNA-binding proteins (RBPs) influences tumor cell sensitivity to chemotherapy.
• RBPs regulate gene expression by binding to mRNA 3'-UTRs or interacting within ribonucleoprotein complexes.

Purpose of the Study:

• To review the role of RBPs in cancer chemoresistance.
• To discuss how RBPs are affected by and actively modulate therapeutic responses.
• To highlight therapeutic strategies targeting RBPs in cancer treatment.

Main Methods:

• Literature review focusing on RNA-binding proteins and chemoresistance.
• Analysis of RBP mechanisms in modulating mRNA translation and protein interactions.
• Discussion of emerging therapeutic strategies targeting RBPs.

Main Results:

• RBPs are implicated in the development of therapy-resistant cancer cells.
• RBPs actively influence tumor cell responses to chemotherapeutic agents.
• Dysregulation of RBPs contributes to cancer progression and treatment failure.

Conclusions:

• RBPs play a critical role in mediating cancer chemoresistance.
• Targeting specific RBPs presents a promising avenue for overcoming therapeutic resistance.
• Further research into RBP-mediated mechanisms can lead to novel cancer therapies.